Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,143,704
  • Shares Outstanding, K 217,373
  • Annual Sales, $ 2,159 M
  • Annual Income, $ 446,910 K
  • 60-Month Beta 1.05
  • Price/Sales 10.34
  • Price/Cash Flow 41.02
  • Price/Book 11.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.61
  • Number of Estimates 2
  • High Estimate 0.61
  • Low Estimate 0.60
  • Prior Year 0.56
  • Growth Rate Est. (year over year) +8.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
89.96 +18.35%
on 06/12/20
110.25 -3.43%
on 06/23/20
+5.57 (+5.52%)
since 06/02/20
3-Month
77.24 +37.84%
on 04/03/20
110.25 -3.43%
on 06/23/20
+29.40 (+38.15%)
since 04/02/20
52-Week
62.48 +70.41%
on 03/23/20
110.25 -3.43%
on 06/23/20
+21.46 (+25.24%)
since 07/02/19

Most Recent Stories

More News
Watch for Incyte Corp to Potentially Pullback After Gaining 3.32% Yesterday

Incyte Corp (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $102.52 to a high of $106.61. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of...

INCY : 106.47 (+3.72%)
Look for Shares of Incyte Corp to Potentially Pullback after Yesterday's 3.32% Rise

Incyte Corp (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $102.52 to a high of $106.61. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of...

INCY : 106.47 (+3.72%)
Gilead Prices Coronavirus Drug Remdesivir at $390 Per Vial

Gilead (GILD) prices experimental coronavirus drug, remdesivir, at $390 per vial.

ALXN : 112.30 (-0.08%)
RHHBY : 43.7900 (-0.55%)
GILD : 76.35 (+0.38%)
INCY : 106.47 (+3.72%)
Bristol Myers & Acceleron Obtain EC Approval for Reblozyl

Bristol Myers (BMY) and partner Acceleron win EC approval of Reblozyl (luspatercept) for two indications.

INCY : 106.47 (+3.72%)
NVS : 87.57 (-0.32%)
BMY : 59.14 (+0.27%)
XLRN : 101.35 (+5.27%)
Global Leukemia Therapeutics Market By Factor, By Severity, By Blood Cell, By Age Groups, By Sex, By Treatment,

, /PRNewswire/ --Read the full report: Leukemia or blood cancer is the cancer of blood forming tissues: bone marrow and lymphatic system.As the name suggests, it affects the leucocytes or white blood...

BMY : 59.14 (+0.27%)
CELGZ : 0.47 (+2.15%)
LLY : 163.87 (+0.35%)
INCY : 106.47 (+3.72%)
MRK : 78.78 (+0.84%)
PKI : 97.94 (+0.88%)
Incyte Announces Approval of Tabrecta(TM) (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14

--- Tabrecta is the third Incyte-discovered molecule to be approved by the MHLW

NVS : 87.57 (-0.32%)
INCY : 106.47 (+3.72%)
Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation

Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.

ALXN : 112.30 (-0.08%)
RHHBY : 43.7900 (-0.55%)
GILD : 76.35 (+0.38%)
INCY : 106.47 (+3.72%)
Alexion's (ALXN) SC Ultomiris Meets Primary Goal in Phase III

Alexion's (ALXN) subcutaneous formulation of Ultomiris meets primary objective in a late-stage study.

ALXN : 112.30 (-0.08%)
GILD : 76.35 (+0.38%)
INCY : 106.47 (+3.72%)
AMGN : 258.24 (+1.22%)
Merck's Keytruda Wins FDA Nod for Squamous Cell Skin Cancer

Merck's (MRK) sBLA for Keytruda for recurrent or metastatic cutaneous squamous cell carcinoma, a form of skin cancer, gets approval from the FDA.

PFE : 34.51 (+2.28%)
MRK : 78.78 (+0.84%)
INCY : 106.47 (+3.72%)
GSK : 41.22 (+0.88%)
Gilead to Start Studies for an Inhaled Version of Remdesivir

Gilead (GILD) announces plans to start studies for an inhaled version of the experimental candidate, remdesivir, in August.

ALXN : 112.30 (-0.08%)
RHHBY : 43.7900 (-0.55%)
GILD : 76.35 (+0.38%)
INCY : 106.47 (+3.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade INCY with:

Business Summary

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis...

See More

Key Turning Points

2nd Resistance Point 110.32
1st Resistance Point 108.39
Last Price 106.47
1st Support Level 103.53
2nd Support Level 100.60

See More

52-Week High 110.25
Last Price 106.47
Fibonacci 61.8% 92.00
Fibonacci 50% 86.36
Fibonacci 38.2% 80.73
52-Week Low 62.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar